# EDGAR Filing Document

**Accession Number:** 0001478242
**File Stem:** 0001193125-25-133449
**Filing Date:** 2025-6
**Character Count:** 11667
**Document Hash:** 55953ae1ab3509d7e2994774b9ab598f
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-25-133449.hdr.sgml**: 20250602

**ACCESSION NUMBER**: 0001193125-25-133449

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20250602

**ITEM INFORMATION**: Other Events

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20250602

**DATE AS OF CHANGE**: 20250602

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** IQVIA HOLDINGS INC.
- **CENTRAL INDEX KEY:** 0001478242
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 271341991
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-35907
- **FILM NUMBER:** 251016151

**BUSINESS ADDRESS:**
- **STREET 1:** 2400 ELLIS ROAD
- **CITY:** DURHAM
- **STATE:** NC
- **ZIP:** 27703
- **BUSINESS PHONE:** 919-998-2000

**MAIL ADDRESS:**
- **STREET 1:** 2400 ELLIS ROAD
- **CITY:** DURHAM
- **STATE:** NC
- **ZIP:** 27703

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Quintiles IMS Holdings, Inc.
- **DATE OF NAME CHANGE:** 20161003

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Quintiles Transnational Holdings Inc.
- **DATE OF NAME CHANGE:** 20091208

?xml version='1.0' encoding='ASCII'? 8-K

### UNITED STATES

### SECURITIES AND EXCHANGE COMMISSION

#### WASHINGTON, D.C. 20549

### FORM 8-K

#### CURRENT REPORT

#### Pursuant to Section 13 or 15(d)

#### of the Securities Exchange Act of 1934

#### Date of Report (Date of earliest event reported): June 2, 2025

## IQVIA HOLDINGS INC.

#### (Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-35907** | **27-1341991** |
| **(State or other jurisdiction**<br> **of incorporation)** | **(Commission**<br> **File Number)** | **(IRS Employer**<br> **Identification No.)** |

---

---

| | |
|:---|:---|
| **2400 Ellis Road**<br> **Durham, North Carolina** | **27703** |
| **(Address of principal executive offices)** | **(Zip Code)** |

---

#### Registrant's telephone number, including area code: (919) 998-2000

#### Not Applicable

#### (Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of Each Class** | **Trading**<br> **Symbol** | **Name of Each Exchange**<br> **on which Registered** |
| Common Stock, par value $0.01 per share | "IQV" | New York Stock Exchange |

---

------

#### Item 8.01 Other Events
On June 2, 2025, IQVIA Holdings Inc. (the "Company") issued a press release announcing that its wholly owned subsidiary, IQVIA Inc. (the "Issuer") intends to raise $2,000,000,000 in gross proceeds through an offering of senior notes due 2032 (the "notes offering") and intends to use the proceeds to repay existing borrowings under the Issuer's revolving credit facility and to pay fees and expenses related to this offering, with any excess proceeds used for other general corporate purposes. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.

On June 2, 2025, the Issuer entered into a purchase agreement with the representative of the purchasers named therein, relating to the issuance and sale of $2,000,000,000 in aggregate principal amount of senior notes due 2032 bearing interest at a rate of 6.250% per annum. The consummation of the notes offering, which is expected to occur on or about June 4, 2025, is subject to the satisfaction of customary closing conditions. The Company also issued a press release announcing the pricing of the notes offering. A copy of the press release is attached as Exhibit 99.2 to this Current Report on Form 8-K.

#### Item 9.01 Financial Statements and Exhibits
(d) Exhibits.

---

| | |
|:---|:---|
| Exhibit No. | Description |
| 99.1 | [Launch press release dated June 2, 2025](d70021dex991.htm) |
| 99.2 | [Pricing press release dated June 2, 2025](d70021dex992.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

------

#### SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: June 2, 2025

---

| | |
|:---|:---|
| **IQVIA HOLDINGS INC.** | **IQVIA HOLDINGS INC.** |
| By: | /s/ Eric M. Sherbet |
|  | Eric M. Sherbet |
|  | Executive Vice President, General Counsel, and Secretary |

---

## Exhibit 99.1

**Exhibit 99.1** 

**IQVIA Announces Offering of Senior Notes** 

June 2, 2025

**RESEARCH TRIANGLE PARK, N.C.** – IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV) today announced that its wholly-owned subsidiary, IQVIA Inc. (the "Issuer"), intends to raise $2,000,000,000 through an offering of senior notes due 2032 (the "Notes").

The proceeds from the Notes offering will be used to repay existing borrowings under the Issuer's revolving credit facility and to pay fees and expenses related to the Notes offering, with any excess proceeds used for other general corporate purposes. The consummation of the Notes offering is subject to market and other customary conditions.

This press release does not constitute an offer to sell or the solicitation of an offer to buy the Notes, nor shall there be any offer, solicitation or sale of the Notes in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful. The Notes to be offered have not been registered under the Securities Act of 1933, as amended (the "Securities Act"), or the securities laws of any other jurisdiction and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act. The Notes are being offered only to persons reasonably believed to be qualified institutional buyers in the United States in reliance on Rule 144A under the Securities Act and outside the United States only to non-U.S. investors pursuant to Regulation S under the Securities Act. Any offer of the Notes will be made only by means of a private offering memorandum.

**About IQVIA** 

IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA's insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors and scientific advances, in an effort to advance their path toward cures.

**Forward Looking Statements** 

Certain statements in this press release are forward-looking statements. These statements involve a number of risks, uncertainties and other factors, including the failure to consummate the Notes offering, and potential changes in market conditions that could cause actual results to differ materially.

**IQVIAFIN** 

Kerri Joseph, IQVIA Investor Relations (kerri.joseph@iqvia.com)

+1.973-541-3558

## Exhibit 99.2

**Exhibit 99.2** 

**IQVIA Announces Pricing of Senior Notes** 

June 2, 2025

**RESEARCH TRIANGLE PARK, N.C.** – IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV) today announced that its wholly-owned subsidiary, IQVIA Inc. (the "Issuer"), priced an offering of $2,000,000,000 in aggregate principal amount of senior notes due 2032 (the "Notes"). The proceeds from the Notes offering will be used to repay existing borrowings under the Issuer's revolving credit facility and to pay fees and expenses related to the Notes offering, with any excess proceeds used for other general corporate purposes.

The Notes will mature on June 1, 2032, unless earlier repurchased or redeemed in accordance with their terms. The Notes will bear interest at a rate of 6.250% per annum and will pay interest semi-annually in arrears on June 1 and December 1 of each year, beginning on December 1, 2025. The issuance of the Notes is expected to occur on or about June 4, 2025, subject to the satisfaction of customary closing conditions.

This press release does not constitute an offer to sell or the solicitation of an offer to buy the Notes, nor shall there be any offer, solicitation or sale of the Notes in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful. The Notes to be offered have not been registered under the Securities Act of 1933, as amended (the "Securities Act"), or the securities laws of any other jurisdiction and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act. The Notes are being offered only to persons reasonably believed to be qualified institutional buyers in the United States in reliance on Rule 144A under the Securities Act and outside the United States only to non-U.S. investors pursuant to Regulation S under the Securities Act. Any offer of the Notes will be made only by means of a private offering memorandum.

**About IQVIA** 

IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA's insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors and scientific advances, in an effort to advance their path toward cures.

**Forward Looking Statements** 

Certain statements in this press release are forward-looking statements. These statements involve a number of risks, uncertainties and other factors, including the failure to consummate the Notes offering, and potential changes in market conditions that could cause actual results to differ materially.

**IQVIAFIN** 

Kerri Joseph, IQVIA Investor Relations (kerri.joseph@iqvia.com)

+1.973-541-3558